Forte Biosciences (FBRX) Other Accumulated Expenses (2016 - 2026)
Forte Biosciences (FBRX) posted quarterly Other Accumulated Expenses of $82000.0 for Q1 2026, down 25.45% year-over-year from $110000.0 in Q1 2025, and up 925.0% quarter-over-quarter from $8000.0 in Q4 2025.
Powered by 
Analysis
Forte Biosciences (FBRX) Other Accumulated Expenses (2016 - 2026) Analysis & Trends
Forte Biosciences (FBRX) has reported Other Accumulated Expenses for 11 consecutive years, with $82000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Accumulated Expenses fell 25.45% year-over-year to $82000.0; the TTM figure through Mar 2026 stood at $82000.0 (down 25.45% YoY), while the FY2025 annual figure was $8000.0, down 93.94% from the prior year.
- Other Accumulated Expenses rose to $82000.0 in Q1 2026 per FBRX's latest filing, from $8000.0 in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $141000.0 in Q1 2022 and bottomed at $3000.0 in Q4 2023.
- Historically, Other Accumulated Expenses has averaged $54750.0 across 5 years, with a median of $43500.0 in 2022.
- Annual changes were most pronounced in 2024 — Other Accumulated Expenses surged 4300.0% — and 2025, when it slumped 93.94%.
- Forte Biosciences' Other Accumulated Expenses stood at $8000.0 in 2022, then slumped by 62.5% to $3000.0 in 2023, then soared by 4300.0% to $132000.0 in 2024, then plunged by 93.94% to $8000.0 in 2025, then soared by 925.0% to $82000.0 in 2026.
- Business Quant data shows FBRX's Other Accumulated Expenses at $82000.0 in Q1 2026, $8000.0 in Q4 2025, and $30000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn |
| 10 | Forte Biosciences | 1.58 Bn | 1.23 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 83,000.00 |
| Mar 31, 2026 | 82,000.00 |
| Dec 31, 2025 | 8,000.00 |
| Sep 30, 2025 | 30,000.00 |
| Jun 30, 2025 | 84,000.00 |
| Mar 31, 2025 | 110,000.00 |
| Dec 31, 2024 | 132,000.00 |
| Sep 30, 2024 | 15,000.00 |
| Jun 30, 2024 | 13,000.00 |
| Dec 31, 2023 | 3,000.00 |
| Sep 30, 2023 | 70,000.00 |
| Jun 30, 2023 | 36,000.00 |
| Mar 31, 2023 | 59,000.00 |
| Dec 31, 2022 | 8,000.00 |
| Sep 30, 2022 | 34,000.00 |
| Jun 30, 2022 | 51,000.00 |
| Mar 31, 2022 | 141,000.00 |
| Dec 31, 2021 | 16,000.00 |
| Sep 30, 2021 | 61,000.00 |
| Jun 30, 2021 | 63,000.00 |